News Search Results
Jan 15, 2026, 23:23 ET The AKG and Ca-AKG of Xin Tianhe have passed the US Self-GRAS certification
manufacturing as its core competitiveness. Relying on the R&D technical strength of its parent company, it has built an internationally advanced synthetic biology technology platform, and has successively obtained KOSHER, FSSC 22000, HALAL, etc., and its technology and quality
More news about: XinTianhe Biotechnology
Jan 15, 2026, 11:45 ET Transition Metal Solutions Closes Oversubscribed $6M Seed to Reinvent Bio-Based Copper Recovery
communities from doing what they naturally evolved to do," said Milshteyn, who has more than 20 years of experience in biophysics, metagenomics, and synthetic biology.When tested on a low-grade primary sulfide ore, lab results showed an increase in copper recovery from 60 to 90 percent. Experiments on
More news about: Transition Metal Solutions
Jan 13, 2026, 10:01 ET Algae-Based Biofuel Market to Reach USD 19.16 Billion by 2032 as Sustainable Aviation Fuel and Energy Security Redefine the Global Fuel Mix
primarily serves pilot and demonstration-scale projects, with activity concentrated in North America.ViridosViridos applies synthetic biology and metabolic engineering to enhance algae productivity for low-carbon fuels and chemicals. The company's innovation centers on strain optimization
More news about: DataM Intelligence 4 Market Research LLP
Jan 13, 2026, 07:00 ET Synthego Announces Entry into Molecular Biology and Clinical Diagnostic Reagents Market
PortfolioThe decision to enter the molecular and clinical diagnostics space is a strategic one for Synthego, leveraging its world-class expertise in synthetic biology and CRISPR-based technologies. By providing novel, engineered enzyme solutions designed for more robust and rapid molecular assays with reagents
More news about: Synthego
Jan 08, 2026, 11:39 ET Bionova Scientific and Syenex Forge Strategic Alliance to Expand Access to High-Quality Plasmid DNA for Advanced Therapies
SyenexSyenex is an open-science genetic medicines platform company that enables developers to program cells with precision and scale. Leveraging synthetic biology and a global network of contract development and manufacturing organizations (CDMOs), Syenex provides plug-and-play delivery platforms, spanning
More news about: Bionova Scientific
Jan 08, 2026, 03:30 ET Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines
trials COVENTRY, England, Jan. 8, 2026 /PRNewswire/ -- NanoSyrinx, a synthetic biology company developing Nanosyringes™ as a novel platform for targeted intracellular delivery of biologic therapeutics, today announced the appointment
More news about: NanoSyrinx
Dec 22, 2025, 13:21 ET Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach
Combining recent advancements in synthetic biology with cutting-edge detection technology, the team expects to develop both a highly innovative orally administered pill containing specially engineered,
More news about: Ginkgo Bioworks
Dec 18, 2025, 09:00 ET Freda Key C Presents Advanced Recombinant Collagen Delivery Technology at SCC79
to account for 44.9% of the total collagen market.Freda's presentation builds on years of research into recombinant collagen. Using its synthetic biology platform, the company has developed highly active, high-purity recombinant humanized Type III collagen and studied its performance in ex vivo
More news about: Shandong Freda Biotech Co., Ltd.
Dec 17, 2025, 08:00 ET Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment
business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Dec 15, 2025, 23:55 ET Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
patients.About BiostarBiostar is an integrated biopharma company focusing on the development of innovative anti-cancer drugs utilizing its synthetic biology R&D platform. The company is listed on the Hong Kong Stock Exchange (HK 2563) in 2024. We are actively selecting reliable global partners
More news about: Biostar Pharma, Inc.
Dec 15, 2025, 08:30 ET Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering
SyenexSyenex is an open-science genetic medicines platform company that enables developers to program cells with precision and scale. Leveraging synthetic biology and a global network of contract development and manufacturing organizations (CDMOs), Syenex provides plug-and-play delivery platforms—spanning
More news about: Leucid Bio
Dec 11, 2025, 10:20 ET Northwestern Innovation Institute Launches International Prize Celebrating Human-Machine Partnerships
Northwestern's commitment to fostering innovation that bridges human and technological capabilities. As artificial intelligence, quantum computing, synthetic biology, and other technologies continue to evolve, the potential for human-machine partnerships to address global challenges has never been greater.The
More news about: Kellogg School of Management
Dec 11, 2025, 09:09 ET AIP Publishing Appoints Yi Cao as Editor-in-Chief of Biophysics Reviews
matter mechanics, mechanobiology, and single-molecule biophysics. His work integrates single-molecule force spectroscopy, polymer chemistry, and synthetic biology to uncover design principles of natural biomaterials and engineer high-performance synthetic materials.He has published more than 190 papers,
More news about: AIP Publishing
Dec 09, 2025, 08:00 ET Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Dec 08, 2025, 10:45 ET Precision Fermentation Market is expected to generate a revenue of USD 34.2 Billion by 2032, Globally, at 40.1% CAGR: Verified Market Research®
competitive advantage.2. Advancements in Synthetic Biology and Fermentation TechnologiesTechnological innovation remains a major accelerator for the Precision Fermentation Market. Modern synthetic biology platforms enable manufacturers to design highly efficient microbial
More news about: Verified Market Research
Dec 05, 2025, 08:33 ET Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High‑Throughput Phenotyping Platform for DOE's M2PC
business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Dec 03, 2025, 18:45 ET CABIO présente l'innovation nutritionnelle à tous les stades de la vie au salon Fi Europe 2025 Paris, à l'occasion de l'ouverture de son nouveau siège mondial.
chinoise, présente son portefeuille complet d'ingrédients nutritionnels tout en annonçant l'ouverture officielle de son nouveau siège mondial, le Synthetic Biology Innovation Hub de Wuhan, marquant ainsi un pas en avant décisif et précurseur dans l'avenir de la biologie synthétique. Un nouveau siège
More news about: CABIO Biotech (Wuhan) Co, Ltd
Dec 03, 2025, 12:11 ET CABIO präsentiert auf der Fi Europe 2025 in Paris Innovationen im Bereich Lebensphasenernährung und eröffnet gleichzeitig seinen neuen globalen Hauptsitz
umfassendes Portfolio an Nahrungsergänzungsmitteln und gibt gleichzeitig die offizielle Eröffnung seines neuen globalen Hauptsitzes – des Wuhan Synthetic Biology Innovation Hub – bekannt, der einen entscheidenden Sprung nach vorne bei der Erschließung der Zukunft der synthetischen Biologie darstellt.
More news about: CABIO Biotech (Wuhan) Co, Ltd
Dec 03, 2025, 09:00 ET CABIO Showcases Life-Stage Nutrition Innovation at Fi Europe 2025 Paris as the New Global Headquarter Opens
announcing the official opening of its new Global Headquarter-Wuhan Synthetic Biology Innovation Hub, marking a pivotal leap forward in pioneering the future of synthetic biology.New Global Headquarter Strengthens Innovation FoundationCABIO's state-of-the-art
More news about: CABIO Biotech (Wuhan) Co, Ltd
Dec 03, 2025, 04:01 ET CABIO Showcases Life-Stage Nutrition Innovation at Fi Europe 2025 Paris as the New Global Headquarter Opens
portfolio while simultaneously announcing the official opening of its new Global Headquarter-Wuhan Synthetic Biology Innovation Hub, marking a pivotal leap forward in pioneering the future of synthetic biology. New Global Headquarter Strengthens Innovation FoundationCABIO's state-of-the-art
More news about: CABIO Biotech (Wuhan) Co, Ltd
Nov 26, 2025, 08:00 ET mAIbe and LenioBio announce a new strategic collaboration aimed at accelerating the discovery and experimental validation of next-generation monoclonal antibodies
mAIbemAIbe is a biotechnology company focused on AI-guided monoclonal antibody design. Its platform combines physics-informed generative AI and synthetic biology to develop precise, cost-effective antibodies targeting viral and bacterial pathogens. Based in Rome, Italy, mAIbe operates at the convergence
More news about: LenioBio
Nov 26, 2025, 03:00 ET mAIbe and LenioBio announce a new strategic collaboration aimed at accelerating the discovery and experimental validation of next-generation monoclonal antibodies
mAIbemAIbe is a biotechnology company focused on AI-guided monoclonal antibody design. Its platform combines physics-informed generative AI and synthetic biology to develop precise, cost-effective antibodies targeting viral and bacterial pathogens. Based in Rome, Italy, mAIbe operates at the convergence
More news about: LenioBio
Nov 20, 2025, 09:43 ET ViVac Appoints Keren Leshem as Chief Executive Officer, Strengthening Leadership to Advance RNA-Lipid Nanoparticle Immunotherapy Platform
JERUSALEM, Nov. 20, 2025 /PRNewswire/ -- ViVac Pharma Ltd., a pioneering synthetic biology company advancing RNA–Lipid Nanoparticle (LNP) immunotherapies, announces the appointment of Keren Leshem as Chief Executive
More news about: ViVac Pharma Ltd.
Nov 18, 2025, 08:00 ET Ginkgo Bioworks Partners on Illinois-Led Team to Develop Innovative New Treatments for Oral Health
business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Nov 13, 2025, 09:27 ET BiomEdit Announces USDA Finding of No Significant Impact Letter for Non-Antibiotic Poultry Biologic, Clearing Path to Field Safety Trials
BiomEdit BiomEdit, Inc., is an animal health microbial biotechnology company leveraging the power of the microbiome and synthetic biology to develop next-generation solutions for livestock and pet health. Founded in 2022, BiomEdit is backed by leading investors including Anterra
More news about: BiomEdit